

# A STUDY OF THE RELATIONSHIP BETWEEN PC-1 GENE POLYMORPHISM AND INSULIN RESISTANCE IN PATIENTS WITH DIABETES TYPE 2 IN THI-QAR GOVERNORATE

Neamat Hadi sabbar, Dr. Hassan Risan Al-Rikabi Department of Biology, Education College of Pure Science, University of Thi-Qar

**Annotation:** The research study was carried out between December and May 2023 at the Biotechnology Research Unit of Thi-Qar at Mazaya University College. was the current study aimed to identify the genetic polymorphisms of 120 samples to investigate the possible association of PC-1 gene polymorphism with the diabetes mellitus. The observed PCR amplicons were subjected to the DNA sequencing procedure. The discovered variants were then localized based on where they were located within the reference genomic DNA sequences. The recent findings showed that the samples under investigation had genetic variations that were unevenly distributed. Besides, the rs1044498, A248C, also the high frequency variant is usually detected in three polymorphic modes, AA, AC, CC. Homozygous AA pattern discovered in the majority of patients (62.5%) and normal specimens (60%). However, each observed SNP was taken a particular pattern of variation differ from its mate in terms of the investigated samples. Ultimately, a statistical analysis is required to evaluate the possible association of the SNPs is tested samples, with the diabetes mellitus. As a result, the PC1 polymorphism was found to be associated with type 2 diabetes mellitus and insulin resistance in the current investigation... Mutations in the PC-1 gene were recorded in the bank gene(NCBi) with accession numbers. LC768831, LC768832, LC768842, LC768843, LC768843.

#### **INTRODUCTION**

The chronic illnesses and health difficulties brought on by diabetes mellitus (DM) are a concern for people all over the world. A rise in hyperglycemia, often known as high blood sugar, is the metabolic condition known as diabetes mellitus (DM). By 2030, more than 280 million adults will have diabetes worldwide, and by 2050, that number will rise to more than 400 million (Shaw *et al.*, 2010). Diabetes is commonly divided into categories (Thomas and Philipson ., 2015). These include autoimmunemediated type 1 diabetes causes insulin deficiency; mellitus, which develops as a result of pancreatic injury; diabetes linked to particular genetic disorders; and a general category known as type 2 diabetes, in which insulin production is impaired and resistance to insulin actions is typically present but not always (American, 2020). Type 1 diabetes results in insulin deficiency. Growing understanding of significant variances in the physiological mechanisms underpinning these different categories has the potential to improve outcomes by making some therapeutic modalities more accessible (American, 2021). Body's incapacity to create or react to insulin is what distinguishes the metabolic syndrome, which includes type 2 diabetes (T2DM). In addition to hypertension, dyslipidemia (low lipid levels), and insulin resistance, which is directly related to the development of T2DM, a major risk factor for metabolic syndrome (Zafa *et al.*, 2019). Attacks on the brain and other heart and circulatory (CVD) illnesses (Martins et al. 2019). Estimates of the high prevalence of a



metabolic disorder and insulin resistance range from 10% to 40% in younger individuals and developing nations (Ansarimoghaddam et al., 2018). In comparison to other T2DM diabetes has the highest prevalence and accounts to over 90% of the worldwide diabetes prevalence (Santoro et al., 2021). In the event that insulin production levels fall for whatever cause or cells develop resistance to insulin, T2D disease will result (Chaudhury et al., 2017). But because they contribute to insulin resistance and type 2 diabetes (T2D), genetic and environmental variables that control how cells respond to insulin are also crucial to be studied (de Veciana et al., 2017). According to the International Diabetes Federation (IDF), diabetes is an endocrine system illness that will affect more than 693 million persons worldwide by the year 2045, up from 50% in 2017 (Cho et al., 2018). Diabetes of type 2 is a clinical syndrome that causes high blood sugar levels, which is due to genetic and environmental risk factors. Diabetes is one of the biggest challenges facing scientific health (Ogurtsova et al., 2017). Unhealthy changes in biological clock and Additionally contributing to metabolic syndrome and insulin resistance is lifestyle. Genetic variables also influence a person's likelihood of developing insulin resistance and the metabolic syndrome (Brown and Walker, 2016). Ectonucleotide Pyrophosphatase-Phosphodiesterase 1 (ENPP1) is another name for the PC1 gene. It is found on the long arm of chromosome 6 (6q23.2) which has 25 exons and 24 introns, and it encodes for a protein that influences the sensitivity of the body to insulin. It is an endogenous transmembrane glycoprotein that can be found in the endoplasmic reticulum (ER) as well as on the plasma membrane. It is possible for the (PCI) to suppress the autophosphorylation of the insulin receptor (IR with direct engaging with the insulin receptor subunit, hence preventing further downstream signaling, despite the fact that its function is not fully understood. (Vickers, 2017; Pappalardo et al., 2017).

# MATERIAL AND METHODS

# Ethical statement

Before the start of the study, institutional approval was obtained, Nasiriyah Teaching Hospital, Thi- Qar, Iraq.

## **DNA extraction**

Genomic DNA was isolated from whole blood using a Geneaid Blood DNA extraction Kit (of Korean origin) after blood was collected in EDTA tubes. in accordance with industrial requirements. Primer-based Polymerase Chain Reaction (PCR) was used.

(F  $\$  5-TCAGAGTGGCCATGGTAGTG-3; R  $\$  5-TGTAAAGCCCCGCTAAGACG-3) rs1044498, a polymorphism in PC1. Digested products and marker DNA (350 bp ladder) were resolved on a 2% agarose gel electrophoresis for scale interpretation.

# RESULTS

A total of 80 cases of T2DM and 40 healthy controls comprised the population analyzed in our study. The demographics and clinical parameters of all participants are shown in Tables 2. The results showed that there was a significant difference in patients with T2D, smokers and non-smokers (OR=0.013), and the duration of infection (OR=0.000), while there was no significant difference in gender, age, and blood pressure as in a Table 1.

The AA frequency appeared without a significant difference, amounting to OR = 1.1, and the frequency CC appeared with a significant difference, amounting to (OR = 0.8) as in a Table 2.



#### EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE Х

| Vol. 3 No. 11 | (Nov - | 2023) | <b>ISSN:</b> | 2795 | <b>-921</b> |
|---------------|--------|-------|--------------|------|-------------|
|---------------|--------|-------|--------------|------|-------------|

| Characteristics           | Case NO:80                 | Control:40  | p Value |  |  |  |  |
|---------------------------|----------------------------|-------------|---------|--|--|--|--|
| Age                       | 56.95±16.13                | 41.97±11.33 | 0.387   |  |  |  |  |
| Sex (%)                   |                            |             |         |  |  |  |  |
| Woman                     | 46.25                      | 37.5        | 0.362   |  |  |  |  |
| Man                       | 53.75                      | 62.5        |         |  |  |  |  |
| Smoking (%)               |                            |             |         |  |  |  |  |
| Smoker                    | 48.75                      | 25          | 0.013*  |  |  |  |  |
| Ex-smoker                 | 51.25                      | 75          |         |  |  |  |  |
| blood pressure (mmHg)     | 41.25                      |             | 0.118   |  |  |  |  |
| Non-blood pressure (mmHg) | 58.75                      |             |         |  |  |  |  |
| Family history(%)         |                            |             |         |  |  |  |  |
| exist                     | 56.25                      |             | 0.264   |  |  |  |  |
| does not exist            | 43.75                      |             |         |  |  |  |  |
|                           | The duration of the injury | 7(%)        |         |  |  |  |  |
| less than a year          | 7.5                        |             |         |  |  |  |  |
| 10 - 1                    | 57.5                       |             | 0.000*  |  |  |  |  |
| 20 - 11                   | 35                         |             |         |  |  |  |  |

Table 1. Description of Anthropometric, clinical, for all volunteers

| <i>PC-1</i> ,248 A>C | Case=80    | Control=40 | OR  | P.V |
|----------------------|------------|------------|-----|-----|
| AA                   | 50( 62.5%) | 24(60%)    | 1.1 | 0.8 |
| AC                   | 2(2.5%)    | 0(0%)      | 2.5 | 0.5 |
| CC                   | 28(35%)    | 16(40%)    | 0.8 | 0.5 |
| AG                   | 0          | 0          | 1   | 1   |
| GG                   | 0          | 0          | 1   | 1   |

Table 2: Genotype frequency among diabetes mellitusand control





#### Discussion

The results of the current study based on the sequencing analysis of the (PC-1)To elucidate the positions of the targeted SNPs with regard to their deposited SNP database of the sequenced 350bp fragment, the corresponding positions of the PC-1 gene was retrieved from the dbSNP server. To find out the nature of these SNPs, a graphical representation was performed concerning the PC-1dbSNP database within chromosome no. 6 (Gen Bank Acc. NC\_000006.12).).By reviewing all the detected fourteen SNPs in the dbSNP engine.



More than 180 million people worldwide suffer from diabetes mellitus, which reaches pandemic proportions. Global projections for 2010 call for an additional growth of about 50%, with the largest increases expected in the developing nations of Africa, Asia, and South America (Zimmet *et al.*, 2011).

It was also known as Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and Plasma Membrane Glycoprotein 1 (*PC-1*). It was situated on the long arm of chromosome 6 (6q23.2) and encoded for the protein that affected insulin sensitivity, among other things. Both the endoplasmic reticulum (ER) and the plasma membrane had a grade II transmembrane glycoprotein.

The molecular mechanism underlying the phenomenon was initially linked to a single synonymous SNP, K121Q17, which allowed the Q allele to have a "gain-of-function" effect that was several times more potent than the K allele in reducing insulin stimulation of IR autophosphorylation, IR substrate-1 phosphorylation, phosphatidylinositol 3-kinase activity, glycogen synthesis, and cell proliferation (Costanzo *et al*, 2001).

Though, the role of *PC-1* was not fully understood, it was able to inhibit the autophosphorylation of insulin receptors by interacting directly with  $\alpha$ -subunit insulin receptors, thereby blocking subsequent downstream signals (Johnson, 2006; Pappalardo *et al.*, 2017).

The results of current study recorded that an association between *PC-1* 248 A>C SNP polymorphism with diabetes mellitus patients (P. value= 0.0001).

But it has been shown that excessive *PC-1* expression inhibits the action of insulin receptors in tyrosine kinase and, as a result, cellular communication in a number of cells. There is still some confusion regarding the *PC-1* protein's functions (Maddux and Goldfine, 2000).

The results of current study were C>T (rs1044498) polymorphism a significantly associated with diabetes mellitus; The present results incorporated with different studies documented the polymorphism is linked to metabolic syndrome, T2DM, and insulin resistance. (Bhatti *et al.*, 2010; Daoming, Marchenko *et al.*, 2018). However, other research has not confirmed a genetic link between the *PC-1* K121Q polymorphism and insulin resistance (Rasmussen *et al.*, 2000). According to Sortica *et al.*, (2015), the *PC1* K121Q polymorphism was a misleading functional alteration since the 121Q variant more strongly binds insulin receptors than the 121K variant does (Costanzo *et al.*, 2001). Additionally, genetic association studies have confirmed and shown that ENPP1 polymorphisms are linked to a risk for T2D, obesity, and a number of metabolic disorders. (Zhao *et al.*, 2011).

Failed to confirm a link between rs1044498 and type 2 diabetes in the Chinese Han population (Zhao *et al.*, 2011). The positive associations were often reported from White (Abate *et al.*, 2005; Moore *et al.*, 2009) and African (Chandalia *et al.*, 2007) populations; while the negative results were found in Moroccan (El Achhab *et al.*, 2009) Chinese, (Chen *et al.*, 2006) Japanese (Keshavarz *et al.*, 2006) and Korean (Seo *et al.*, 2008) populations. Indeed, demographic variation must be considered, particularly in the case of a complex metabolic condition. Furthermore, T2D and obesity should be attributed to multifactorial etiology, rather than a single gene disease, as a result of changes in several gene products.

In present results of genotype distribution of *PC-1* gene documented that the AA genotype was identified in the majority of case samples (62.5%), and controls (60%), while AC pattern was detected only in case samples (2.5%). The present results were incorporated with results of . Research done in China also revealed that T2DM or any of the characteristics of the metabolic syndrome have no correlation with *PC-1* K121Q polymorphotype distribution (Daoming *et al.*, 2006). The present findings differed from those of Abdo Albegali *et al.* (2019), who found a correlation between *PC-1* and the incidence of diabetes type 2 in the Punjabi population of Pakistan. While many studies have showed no link by this allele and illness risk (Rasmussen *et al.*, 2000), prior research has demonstrated a correlation between the Q allele of *PC1* 



(rs1044498) and insulin resistance(IR) (Gu *et al.*, 2000). Very few reports about the role of *PC1* risk alleles in disease have come from the South Asian continent (Prakash *et al.*, 2013).

Positive findings and proven genetic connections were found in a meta-analysis of the *PC1* K121Q polymorphism and T2DM risk (Abate *et al.*, 2005; Hamaguchi *et al.*, 2004), specific molecular mechanism of this gene's risk factor is still unknown (Abdo Albegali *et al.*, 2019).

Many diseases, including different genetic polymorphisms and risk alleles in this gene have been linked to coronary heart disease, polycystic ovarian disease, obesity, risk of diabetic kidney disease, coronary artery calcification, ischemia of the heart, and T2DM. (Di *et al.*, 2018; Li *et al.*, 2016; Pappalardo *et al.*, 2017).

Some studies recorded relation between the same rs1044498 and other disease that detectesuch as: (Zhang *et al.*, 2021) Hemodialysis patients in the participants recruited from one hospital in China showed the variations of ENPP1 (rs1044498). According to a review, T2DM patients in Asia were the basis for the rs1044498 variation.

### References

- 1. Abate, N., Chandalia, M., Satija, P., Adams-Huet, B., Grundy, S. M., Sandeep, S., ... & Mohan, V. (2005). ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes. *Diabetes*, *54*(4), 1207-1213.
- 2. Albegali, A. A., Shahzad, M., Ullah, M. I., Mahmood, S., & Rashid, M. (2019). Association of genetic polymorphism of PC-1 gene (rs1044498 Lys121Gln) with insulin-resistant type 2 diabetes mellitus in Punjabi Population of Pakistan. *Molecular genetics & genomic medicine*, 7(8), e775.
- 3. Ansarimoghaddam, A., Adineh, H. A., Zareban, I., Iranpour, S., HosseinZadeh, A., & Kh, F. (2018). Prevalence of metabolic syndrome in Middle-East countries: Meta-analysis of cross-sectional studies. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, *12*(2), 195-201..
- 4. American Diabetes Association. (2020). 2. Classification and diagnosis of diabetes:standards of medical care in diabetes. *Diabetes care*, *43*(Supplement\_1), S14-S31.
- 5. American Diabetes Association. (2021). Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2021. *Diabetes care*, 44(Supplement\_1), S111-S124.
- 6. Bhatti, J. S; Bhatti, G. K; Mastana, S. S; Ralhan, S; Joshi, A.and Tewari, R. (2010). ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes in North Indians. Molecular and Cellular Biochemistry, 345(1–2), 249–257.
- 7. Brown, A. E; and Walker, M. (2016). Genetics of insulin resistance and the metabolic syndrome. *Current cardiology reports*, 18, 1-8.
- Chandalia, M., Grundy, S. M., Adams-Huet, B. and Abate, N. Ethnic differences in the frequency of ENPP1/PC1 121Q genetic variant in the Dallas Heart Study cohort. J. Diabetes Complications. 21, 143– 148 (2007).
- 9. Chaudhury, A; Duvoor, C; Reddy Dendi, V. S; Kraleti, S; Chada, A; Ravilla, R; and Mirza, W. (2017). Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. *Frontiers in endocrinology*, *8*, 6.
- Chen, M. P., Chung, F. M., Chang, D. M., Tsai, J. C., Huang, H. F., Shin, S. J. *et al.*,(2006). ENPP1 K121Q polymorphism is not related to type 2 diabetes mellitus, features of metabolic syndrome, and diabetic cardiovascular complications in a Chinese population. Rev. Diabet. Stud. 3, 21–30.



- 11. Cho, N; Shaw, J. E; Karuranga, S; Huang, Y; da Rocha Fernandes, *et al.*, (2018). IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes research and clinical practice, 138, 271-281.
- 12. Costanzo, B. V., Trischitta, V., Di paola, R., Spampinato, D., Pizzuti, A., Vigneri, R. and Frittitta, I. (2001). The Q allele variant (Gln121) of membrane glycoprotein PC-1 interacts with the insulin receptor and inhibits insulin signaling more effectively than the common K allele variant (Lys121). *Diabetes*, *50*, 831–836.
- 13. Daoming, Z; Chaoren, C; Xijun, X; &Junjun, L. (2006). ENPP1 K121Q Polymorphism is not related to type 2 diabetes mellitus; features of metabolic syndrome; and diabetic cardiovascular complications in a Chinese population. *Review of Diabetic Studies*, *3*, 21–30.
- Di, J. Y; Dai, M. L; and Zhang, Z. X. (2018). ENPP1 K121Q (rs1044498 C> A) genetic polymorphism confers a high risk of susceptibility to coronary heart disease. A PRISMA-compliant Article. Medicine 97(27), e11236.
- 15. Veciana, M; Major, C. A; Morgan, M. A; Asrat, T; Toohey, J. S; and Lien, J. M. (2017). Postprandial versus preprandial blood 21. Classification and diagnosis of diabetes. American Diabetes Association. *Diabetes Care*, 40, S11-24.
- 16. Vickers, N. J. (2017). Animal communication: when i'm calling you, will you answer too?. *Current biology*, 27(14), R713-R715.
- 17. El Achhab, Y., Meyre, D., Bouatia-Naji, N., Berraho, M., Deweirder, M., Vatin, V. *et al.*,(2009).Association of the ENPP1 K121Q polymorphism with type 2 diabetes and obesity in the Moroccan population. Diabetes Metab. 35, 37–42.
- 18. Gu, H. F., Almgren, P., Lindholm, E., Frittitta, L., Pizzuti, A., Trischitta, V., &
- 19. Groop, L. C. (2000). Association between the human glycoprotein PC-1 gene and elevated glucose and insulin levels in a paired-sibling analysis. *Diabetes*, *49*(9), 1601–1603.
- 20. Johnson, K. A. (2006). *Transglutaminase mediation of pathologic chondrogenic differentiation in cartilage and aortic smooth muscle*. University of California, San Diego.
- 21. Li, N., Pan, H., Cui, M., and Li, Q. (2016). Association of K121Q polymorphismin ectonucleotidepyrophosphatase/phosphodiesterase 1 with clinical characteristics of metabolic syndrom. Experimental and Clinical Endocrinology & Diabetes, 124(05), 313–317.
- 22. Maddux, B. A., and Goldfine, I. D. (2000). Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with the receptor alpha-subunit. *Diabetes*, 49(1), 13–19.
- 23. Marchenko, I. V., Dubovyk, Y. I., Matlai, O. I., Biesiedina, A. A., Kniazkova, P. V., &Harbuzova, Y. A. (2018). The analysis of association between ENPP1 K121Q polymorphism and risk factors of type 2 diabetes mellitus in Ukrainian population. *WiadomosciLekarskie*, *71*(4), 815–820. Russian.
- 24. Martins, A. D., Majzoub, A., & Agawal, A. (2019). Metabolic syndrome and male fertility. *The world journal of men's health*, 37(2), 113-127.
- 25. Moore, A. F., Jablonski, K. A., Mason, C. C., McAteer, J. B., Arakaki, R. F., Goldstein, B.J. *et al.*, (2009). The association of ENPP1 K121Q with diabetes incidence is abolished bylifestyle modification in the diabetes prevention program. J.clin. endocrinol. metab. 94,449–455.



- 26. Ogurtsova, K., da Rocha Fernandes, J. D., Huang, Y., Linnenkamp, U., Guariguata, L., Cho, N. H., ... and Makaroff, L. E. (2017). IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. *Diabetes research and clinical practice*, *128*, 40-50.
- 27. Keshavarz, P; Inoue, H; Sakamoto, Y; Kunika, K; Tanahashi, T; Nakamura, N.*et al.*,(2006). No evidence for association of the ENPP1 (PC-1) K121Q variant withrisk of type 2 diabetes in a Japanese population. J. Hum. Genet. 51, 559–566.
- 28. Rasmussen, S. K; Urhammer, S. A., Pizzuti, A; Echwald, S. M., Ekstrom, C. T., Hansen, L., ... Pedersen, O. (2000). The K121Q variant of the human PC-1 gene is not associated with insulin resistance or type 2 diabetes among Danish Caucasians. *Diabetes*, 49(9), 1608–1611.
- 29. Prakash, J; Mittal, B; Awasthi, S; Agarwal, C. G; and Srivastava, N. (2013). K121Q ENPP1/PC-1 gene polymorphism is associated with insulin resistance in a North Indian population. *Journal of Genetics*, 92(3), 571–576.
- 30. Seo, H. J., Kim, S. G. and Kwon, O. J., (2008). The K121Q polymorphism in ENPP1 (PC-1) is notassociated with type 2 diabetes or obesity in Korean male workers. J. Korean. Med. Sci.23, 459–464.
- 31. Thomas, C. C; and Philipson, L. H. (2015). Update on diabetes classification. *Medical Clinics*, 99(1), 1-16.
- 32. Pappalardo, M. A; Vita, R; Di Bari, F; Le Donne, M; Trimarchi, F; and Benvenga, S. (2017). Gly972Arg of IRS-1 and Lys121Gln of PC-1 polymorphisms act in opposite way in polycystic ovary syndrome. *Journal of Endocrinology Investigation*, 40(4), 367–376.
- 33. Rasmussen, S. K; Urhammer, S. A; Pizzuti, A; Echwald, S. M; Ekstrom, C. T; Hansen, L., … Pedersen, O. (2000). The K121Q variant of the human PC-1 gene is not associated with insulin resistance or type 2 diabetes among Danish Caucasians. *Diabetes*, 49(9), 1608–1611. https://doi.org/10.2337/diabetes.49.9.1608.
- 34. Zafar, U; Khaliq, S; Ahmad, H. U; and Lone, K. P. (2019). Serum profile of cytokines and their genetic variants in metabolic syndrome and healthy subjects: a comparative study. *Bioscience reports*, *39*(2), BSR20181202.
- 35. Zhao, T.; Liu, Z.; Di Zhang, D. *et al.*, (2011). The ENPP1 K121Q polymorphism is not associated with type 2 diabetes or obesity in the Chinese Han population. Journal of Human Genetics. 56, 12–16.
- 36. Zhang, X.; Wan, Z.; *et al.*, (2021). Association of the ENPP1/ENTPD1 Polymorphisms in Hemodialysis Patients. International Journal of General Medicine. 14: 6401–6408
- 37. Zimmet, P., Alberti, K. G. and Shaw, J. Global and societal implications of the diabetes epidemic. Nature. 414, 782–787 (2001).
- 38. Zhao, T.; Liu, Z.; Zhang, D. *et al.*, (2011). The ENPP1 K121Q polymorphism is not associated with type 2 diabetes or obesity in the Chinese Han population. Journal of Human Genetics. 56, 12–16.